NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1247.40 7.40 (0.60%)

1.1M NSE+BSE Volume

NSE 23 Jul, 2025 3:31 PM (IST)

104,105.7

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Rapid Results

Q1FY26 Quarterly Result Announced for Dr. Reddy's Laboratories Ltd. See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

08 Nov 2019

1247.40

0.60%

Dr. Reddy`s Laboratories Limited

Results Update: Dr. Reddy's Laboratories Ltd.

SMC online

estimates. Quarterly profit jumped more than twofold on the back of a one-time tax gain and higher licence fees from sale of brands Revenues Rs.4,812Cr [YoY: 26% Up QoQ: 25% ], Gross Margin 57.50% [Q2 FY20: 51.7%; Q2 FY19: 55%], SG&A; expenses Rs.1678 crore [YoY: 36%; QoQ: 39%], R&D; expenses Rs.366 crore [7.6% of Revenues], Profit before Tax Rs.766 crore [YoY: 33% Up QoQ: -10%],...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

04 Nov 2019

1247.40

0.60%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Revenues grew 26.1% YoY to | 4812.8 crore (I-direct estimate: | 4587.1 crore) on the back of sale of three proprietary products (| 720 crore). EBITDA margins expanded 221.4 bps to 22.1% (I-direct estimate: 26.6%) mainly due to sale of proprietary products and lower R&D; spend. Delta vis--vis I-direct estimates was mainly due to an adverse product mix. EBITDA grew 40.1% YoY to | 1063.8 crore against I-direct estimate of | 1222.0 crore. Net profit grew 113.5% YoY to | 1106.8 crore (I-direct estimate: | 790.0 crore). Delta vis--vis EBITDA mainly due to lower tax outgo led by recognition of...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

04 Nov 2019

1247.40

0.60%

Dr. Reddys Lab: Licencing Income coupled with tax credit boost profits

Buy: Dr. Reddy's Laboratories Ltd.

Karvy

Dr.Reddys Lab s (DRL) revenue, increased by 26.4 percent YoY to Rs 48bn, is higher than our estimates of Rs43.3 bn, primarily due to good growth in Domestic, Europe and Emerging market and licence fees for three proprietary products.

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1294.1

Dr. Reddy's Laboratories Ltd.

02 Nov 2019

1247.40

0.60%

Ex-US trends favorable, cost-cut benefits visible

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

PSAI/EM/EU drive growth: Adjusting for one-time income of INR7.2b as license fee for two brands, sales increased 7.5% YoY to INR40.8b (our estimate: INR41.9b) in 2QFY20, led by PSAI (+18% YoY), EMs (+10% YoY) and Europe (+44% YoY), partly offset by muted growth in the US (flat YoY). For...

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1294.1

Dr. Reddy's Laboratories Ltd.

01 Nov 2019

1247.40

0.60%

Q2FY20 Result Update

Accumulate: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

control on overheads with its ongoing program of rationalized assets, products and global presence. Employee and SGA costs decreased by 2% and 1% respectively, while R&D; costs increased only by 1% QoQ. Its adoption of new strategy with cost-benefit analysis of each operational activity helps to limit the reduction of adj. EBITDA margin only by 20bps QoQ to 19.2%, despite one-off inventory adjustment, adverse forex (USD/INR), price erosion in core US generis and recalls of Ranitidine. Adjusted with one-off income of...

Dr. Reddy's Laborato.. has an average target of 1321.50 from 8 brokers.

Dr. Reddy's Laboratories Ltd.

25 Sep 2019

1247.40

0.60%

Dr Reddys Lab: Pursuing profitable avenues of growth

Buy: Dr. Reddy's Laboratories Ltd.

Target

Karvy

We interacted with Dr Reddys Lab management recently.

Geojit BNP Paribas released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1150.0 on 07 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

06 Aug 2019

1247.40

0.60%

Dr. Reddy's Laboratories Ltd. - Result Update - 06 August 2019

Results Update: Dr. Reddy's Laboratories Ltd.

Way2Wealth

Dr. Reddy's reported a weak set of operating numbers. Consolidated revenue of `38,435 mn in Q1FY20, growth of 3% YoY and a decline of 4% QoQ. During the quarter, the company received an amount of `3457 mn (Other income) from Celgene as a settlement agreement related to Revlimid that elevated EBITDA and Net profit. Adjusted EBITDA grew by only 10% YoY to `8,789 during the quarter. Whilst EBITDA margin came in at 20%, decline of 98bps YoY. Gross profit margin for the quarter was...

Dr. Reddy's Laboratories Ltd. is trading above its 200 day SMA of 1245.0

Dr. Reddy's Laboratories Ltd.

06 Aug 2019

1247.40

0.60%

Dr Reddys Laboratories Limited

Results Update: Dr. Reddy's Laboratories Ltd.

SMC online

Other operating income at Rs.380 crore; includes Rs.350 crore received from Celgene pursuant to an agreement entered towards settlement of any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company's ANDS for a generic version of...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

02 Aug 2019

1247.40

0.60%

Result Update:Dr Reddys Labs

Buy: Dr. Reddy's Laboratories Ltd.

Axis Direct

Dr. Reddy's Lab. (DRRD) reported mixed performance in Q1FY20, with revenue at Rs3,843Cr (vs. estimate of Rs3,931Cr), below expectation on account of softness in PSAI segment (down 33%/16% on QoQ/YoY) and Proprietary product (due to divested assets).

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

30 Jul 2019

1247.40

0.60%

Dr. Reddy's Labs (1QFY20): Favourable valuations. Maintain BUY

Buy: Dr. Reddy's Laboratories Ltd.

Target

HDFC Securities

Having overcome regulatory issues at key formulations plants, the co is rapidly ramping up US revenues with key oncology and injectables launches. Additionally, biosimilar and complex generics launches in EM and reg markets, renewed focus on India, and traction gained in EU & China will support rev CAGR of ~15% over FY19-21E. Mr Erez Israeli has now stepped up as the CEO, following a successful stint as COO with ~400bps improvement in EBITDA margin during FY19. Continued cost optimization, divestment of non-core assets, and healthy revenue growth across key geographies along with a better mix will drive ~19% PAT CAGR over FY19-21E. Considering the improving balance sheet, healthy FCF (Rs 15bn+ annually), and largely clear regulatory status, the valuations remain lucrative at 20.7/17.8x FY20/21E P/E. We maintain BUY on DRRD following a miss on our estimates driven by temporary issues. Our TP is unchanged at Rs 3,360 (20x FY21E EPS + Rs 380/sh for niche products). A visible ramp up in the US and further cost efficiencies enable us to stay confident.

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1294.1

Is Dr. Reddy's Laboratories Ltd. worth buying?

517 Votes:

Buy 78.34%

Sell 11.99%

Hold 9.67%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf